{"url_path":"/sec/pvla/8-k/2026-05-13/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001193125-26-220607-index.html","accession_number":"0001193125-26-220607","cik":"0001583648","ticker":"PVLA","issuer_name":"PALVELLA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001193125-26-220607-index.html","primary_entity_key":"0001583648","primary_entity_name":"PALVELLA THERAPEUTICS, INC."},"word_count":111,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn May 11, 2026, Palvella Therapeutics, Inc. (the “Company”) received approval from the Nasdaq Listing Qualifications Department to move the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective with the open of business on May 13, 2026. The Company’s existing ticker symbol, “PVLA,” will not be affected by such exchange tier transfer.\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nPalvella Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 13, 2026\n\nBy:\n\n/s/ Matthew Korenberg\n\n \n\n \n\n \n\nMatthew Korenberg\n\n \n\n \n\n \n\nChief Financial Officer"}